Sangamo BioSciences, Inc. (NASDAQ: SGMO) announced today that preliminary data from the University of Pennsylvania investigator sponsored Phase 1 safety ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE